ADMA
ADMA Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.62
+0.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 512.3M | 510.2M | 426.5M | 258.2M | 154.1M |
| Cost of Revenue | 180.8M | 217.4M | 206.9M | 169.3M | 118.8M |
| Gross Profit | 331.5M | 292.8M | 219.6M | 88.9M | 35.3M |
| Operating Expenses | |||||
| R&D Expense | 11.5M | 4.8M | 1.8M | 3.3M | 3.6M |
| SG&A Expense | 100.0M | 91.6M | 74.1M | 59.0M | 52.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 3.4M | 5.0M | 4.6M | 5.0M | 18.6M |
| Total Operating Expenses | 114.9M | 101.3M | 80.6M | 67.3M | 74.6M |
| Cost and Expenses | 295.8M | 318.7M | 287.5M | 236.6M | 193.4M |
| Operating Income (EBIT) | 216.5M | 191.4M | 139.0M | 21.6M | (39.4M) |
| Non-Operating | |||||
| Interest Income | 3.2M | 1.9M | 2.1M | 1.6M | 44.8K |
| Interest Expense | 8.8M | 7.1M | 13.9M | 25.0M | 19.3M |
| Net Interest Income | (5.6M) | (5.2M) | (11.8M) | (23.4M) | (19.2M) |
| Other Non-Op Income/Expense | (28.0K) | (8.8M) | (13.3M) | (49.9M) | (26.5M) |
| Non-Operating Income (excl Interest) | (8.8M) | 1.7M | (661.0K) | 24.8M | 7.3M |
| EBT (Pre-Tax Income) | 216.5M | 182.7M | 125.7M | (28.2M) | (65.9M) |
| Income Tax Expense | 47.5M | 35.7M | (72.0M) | — | — |
| Bottom Line | |||||
| Net Income | 169.0M | 146.9M | 197.7M | (28.2M) | (65.9M) |
| Earnings from Cont. Ops | 169.0M | 146.9M | 197.7M | (28.2M) | (65.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 169.0M | 146.9M | 197.7M | (28.2M) | (65.9M) |
| Per Share | |||||
| Basic EPS | $0.72 | $0.62 | $0.85 | ($0.13) | ($0.43) |
| Diluted EPS | $0.70 | $0.60 | $0.81 | ($0.13) | ($0.43) |
| Revenue Per Share | $2.24 | $2.14 | $1.83 | $1.15 | $0.78 |
| Shares | |||||
| Basic Shares Outstanding | 228.2M | 238.3M | 233.1M | 224.0M | 197.9M |
| Diluted Shares Outstanding | 230.3M | 244.9M | 243.3M | 224.0M | 197.9M |
| Profitability Metrics | |||||
| EBITDA | 234.8M | 197.9M | 147.7M | 5.1M | (39.5M) |
| D&A | 9.5M | 8.1M | 8.0M | 8.3M | 7.1M |
| EBIT | 225.3M | 189.8M | 139.6M | (3.2M) | (46.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026